JP2007522176A5 - - Google Patents

Download PDF

Info

Publication number
JP2007522176A5
JP2007522176A5 JP2006552565A JP2006552565A JP2007522176A5 JP 2007522176 A5 JP2007522176 A5 JP 2007522176A5 JP 2006552565 A JP2006552565 A JP 2006552565A JP 2006552565 A JP2006552565 A JP 2006552565A JP 2007522176 A5 JP2007522176 A5 JP 2007522176A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
hydrogen
alkenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006552565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522176A (ja
JP5001012B2 (ja
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed filed Critical
Priority claimed from PCT/EP2005/001449 external-priority patent/WO2005077950A2/en
Publication of JP2007522176A publication Critical patent/JP2007522176A/ja
Publication of JP2007522176A5 publication Critical patent/JP2007522176A5/ja
Application granted granted Critical
Publication of JP5001012B2 publication Critical patent/JP5001012B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006552565A 2004-02-14 2005-02-10 Ｈｍ７４ａ受容体活性を有する薬剤 Expired - Fee Related JP5001012B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0403282.7 2004-02-14
GB0423562.8 2004-10-22
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
GB0428375.0 2004-12-24
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008030344A Division JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Publications (3)

Publication Number Publication Date
JP2007522176A JP2007522176A (ja) 2007-08-09
JP2007522176A5 true JP2007522176A5 (https=) 2008-04-03
JP5001012B2 JP5001012B2 (ja) 2012-08-15

Family

ID=34864831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006552565A Expired - Fee Related JP5001012B2 (ja) 2004-02-14 2005-02-10 Ｈｍ７４ａ受容体活性を有する薬剤
JP2008030344A Expired - Fee Related JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008030344A Expired - Fee Related JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Country Status (25)

Country Link
US (5) US7713982B2 (https=)
EP (1) EP1781657B1 (https=)
JP (2) JP5001012B2 (https=)
KR (1) KR101100601B1 (https=)
CN (2) CN101103030B (https=)
AR (1) AR047669A1 (https=)
AU (1) AU2005212816C1 (https=)
BR (1) BRPI0507604A (https=)
CA (1) CA2556073C (https=)
CY (1) CY1114022T1 (https=)
DK (1) DK1781657T3 (https=)
ES (1) ES2406732T3 (https=)
HR (1) HRP20130406T1 (https=)
IL (1) IL177051A (https=)
MA (1) MA28357A1 (https=)
MY (1) MY148937A (https=)
NO (1) NO337281B1 (https=)
NZ (1) NZ548496A (https=)
PE (1) PE20060317A1 (https=)
PL (1) PL1781657T3 (https=)
PT (1) PT1781657E (https=)
SG (1) SG157242A1 (https=)
SI (1) SI1781657T1 (https=)
TW (1) TWI350289B (https=)
WO (1) WO2005077950A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610133A2 (pt) 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
MX2007015867A (es) * 2005-06-14 2008-03-04 Hoffmann La Roche Derivados del acido antranilico.
SI1901731T1 (sl) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
BRPI0615145A2 (pt) * 2005-08-10 2009-11-03 Smithkline Beecham Corp derivados de xantina como agonistas hm74a seletivos
CN101400682A (zh) * 2006-01-20 2009-04-01 先灵公司 治疗异常脂血症的杂环烟酸受体激动剂
DE602007006947D1 (de) * 2006-05-23 2010-07-15 Hoffmann La Roche Pyridopyrimidinonderivate
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
KR20090025262A (ko) 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
WO2007150025A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
EP2139895A1 (en) * 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
US9163024B2 (en) * 2008-12-08 2015-10-20 Glaxosmithkline Llc Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
CA2973746C (en) * 2015-01-30 2020-03-24 Shanton Pharma Co., Ltd. Prevention or treatment of uratic or gouty diseases
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
AU2020356570A1 (en) * 2019-09-25 2022-05-12 Goldfinch Bio, Inc. Xanthine CB1 inhibitors
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
US20260035370A1 (en) 2023-02-27 2026-02-05 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
DE69332634T2 (de) 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AU4205000A (en) 1999-04-09 2000-11-14 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
EP1208100B1 (en) * 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
AU2001276023A1 (en) * 2000-07-21 2002-02-05 Mark B Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
BRPI0615145A2 (pt) 2005-08-10 2009-11-03 Smithkline Beecham Corp derivados de xantina como agonistas hm74a seletivos
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
US9163024B2 (en) * 2008-12-08 2015-10-20 Glaxosmithkline Llc Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Similar Documents

Publication Publication Date Title
JP2007522176A5 (https=)
CA2556073A1 (en) 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
US11013722B2 (en) Therapeutic agent for dyslipidemia
HRP20100725T1 (hr) Derivati ksantina kao selektivni agonisti hm74a
JP2004522714A5 (https=)
JP2007502263A5 (https=)
JP7022066B2 (ja) 代謝機能不全によって引き起こされる腫瘍の治療
JP2016500063A5 (https=)
JP2011512856A5 (https=)
US20160221933A1 (en) Compositions for the treatment of hypertension and/or fibrosis
CN1454054A (zh) 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进
CN101823956B (zh) 非诺贝特酸二异丙胺盐、其制备方法, 药物组合物及其用途
EP2945618A1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
RU2742418C1 (ru) Лекарственные формы, содержащие оксалатные соли тенелиглиптина и их сольваты
JP2016505039A5 (https=)
EP1882474A1 (en) Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism
B Ghatak et al. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus
JP2009506043A5 (https=)
RU2006132925A (ru) Новые соединения
JP2012511028A5 (https=)
WO2011141419A1 (en) Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
JP2020520904A5 (https=)
US20230051268A1 (en) Use of lemborexant for treating insomnia
WO2001039769A1 (en) Hypoglycemics comprising organic zinc (ii) complexes